PL2558105T3 - Metylowany bardoksolon do leczenia otyłości - Google Patents

Metylowany bardoksolon do leczenia otyłości

Info

Publication number: PL2558105T3
Authority: PL; Poland
Prior art keywords: obesity; treatment; bardoxolone methyl; bardoxolone; methyl
Prior art date: 2010-04-12

Application number

PL11715645T

Other languages

English (en)

Inventor

Colin J. Meyer

Warren Huff

Original Assignee

Reata Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-12

Filing date

2011-04-12

Publication date

2020-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44259866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2558105(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-04-12 Application filed by Reata Pharmaceuticals, Inc. filed Critical Reata Pharmaceuticals, Inc.

2020-04-30 Publication of PL2558105T3 publication Critical patent/PL2558105T3/pl

Links

WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical group C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 title 1
208000008589 Obesity Diseases 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Child & Adolescent Psychology (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

PL11715645T 2010-04-12 2011-04-12 Metylowany bardoksolon do leczenia otyłości PL2558105T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US32327610P	2010-04-12	2010-04-12
US38909010P	2010-10-01	2010-10-01
EP11715645.5A EP2558105B1 (en)	2010-04-12	2011-04-12	Bardoxolone methyl for the treatment of obesity
PCT/US2011/032156 WO2011130302A2 (en)	2010-04-12	2011-04-12	Method of treating obesity using antioxidant inflammation modulators

Publications (1)

Publication Number	Publication Date
PL2558105T3 true PL2558105T3 (pl)	2020-04-30

Family

ID=44259866

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11715645T PL2558105T3 (pl)	2010-04-12	2011-04-12	Metylowany bardoksolon do leczenia otyłości

Country Status (31)

Country	Link
US (3)	US10105372B2 (pl)
EP (1)	EP2558105B1 (pl)
JP (1)	JP5990160B2 (pl)
KR (1)	KR101819699B1 (pl)
CN (1)	CN102939089B (pl)
AU (1)	AU2011240690C1 (pl)
BR (1)	BR112012026112B1 (pl)
CA (1)	CA2795320C (pl)
CL (1)	CL2012002859A1 (pl)
CY (1)	CY1122480T1 (pl)
DK (1)	DK2558105T3 (pl)
EA (1)	EA026567B1 (pl)
ES (1)	ES2768204T3 (pl)
HR (1)	HRP20192291T1 (pl)
HU (1)	HUE047994T2 (pl)
IL (1)	IL222273B (pl)
LT (1)	LT2558105T (pl)
ME (1)	ME03713B (pl)
MX (1)	MX357596B (pl)
MY (1)	MY163031A (pl)
NZ (1)	NZ602826A (pl)
PH (1)	PH12012502041B1 (pl)
PL (1)	PL2558105T3 (pl)
PT (1)	PT2558105T (pl)
RS (1)	RS59850B1 (pl)
SG (2)	SG10201808661XA (pl)
SI (1)	SI2558105T1 (pl)
SM (1)	SMT202000086T1 (pl)
TW (1)	TWI558724B (pl)
WO (1)	WO2011130302A2 (pl)
ZA (1)	ZA201207518B (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6326507B1 (en)	1998-06-19	2001-12-04	Trustees Of Dartmouth College	Therapeutic compounds and methods of use
HUE043175T2 (hu)	2008-01-11	2019-08-28	Reata Pharmaceuticals Inc	Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
MX339476B (es)	2008-04-18	2016-05-27	Reata Pharmaceuticals Inc	Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
CN104250280A (zh)	2008-04-18	2014-12-31	里亚塔医药公司	抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
ES2703274T3 (es)	2008-04-18	2019-03-07	Reata Pharmaceuticals Inc	Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
KR101713140B1 (ko)	2008-04-18	2017-03-08	리타 파마슈티컬스 잉크.	Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
EP2309860B1 (en)	2008-07-22	2014-01-08	Trustees of Dartmouth College	Monocyclic cyanoenones and methods of use thereof
SMT202000086T1 (it)	2010-04-12	2020-03-13	Reata Pharmaceuticals Inc	Bardoxolone metile per il trattamento dell'obesità
HRP20171859T1 (hr)	2010-12-17	2018-01-26	Reata Pharmaceuticals, Inc.	Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale
CA2829618C (en)	2011-03-11	2019-07-09	Reata Pharmaceuticals, Inc.	C4-monomethyl triterpenoid derivatives and methods of use thereof
KR101174701B1 (ko) *	2011-12-29	2012-08-17	서울대학교산학협력단	진저레논 에이를 포함하는 비만 예방용 식품 조성물, 비만 치료용 약학조성물 및 비만 치료용 동물용 의약품
DK3444261T3 (da)	2012-04-27	2021-03-08	Reata Pharmaceuticals Inc	2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser
US9556222B2 (en)	2012-06-15	2017-01-31	Reata Pharmaceuticals, Inc.	A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9278912B2 (en)	2012-09-10	2016-03-08	Reata Pharmaceuticals, Inc.	C13-hydroxy derivatives of oleanolic acid and methods of use thereof
MX2015003021A (es) *	2012-09-10	2015-11-09	Abbvie Inc	Derivados de acido glicirretinico y metodos de uso de los mismos.
US9512094B2 (en)	2012-09-10	2016-12-06	Reata Pharmaceuticals, Inc.	C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
PL2892912T3 (pl)	2012-09-10	2019-10-31	Reata Pharmaceuticals Inc	C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
US9968575B2 (en)	2012-09-27	2018-05-15	The Children's Medical Center Corporation	Compounds for the treatment of obesity and methods of use thereof
TW201514192A (zh)	2013-03-19	2015-04-16	Daiichi Sankyo Co Ltd	萜類衍生物
TWI649330B (zh)	2013-04-24	2019-02-01	艾伯維有限公司	甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法
NZ774222A (en) *	2013-08-23	2023-01-27	Reata Pharmaceuticals Holdings Llc	Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
MX372772B (es)	2014-01-24	2020-06-29	Reata Pharmaceuticals Inc	Enonas piridazolilo y pirimidinilo tricíclicas sustituidas con arilo y arilalquilo como moduladores de la inflamación antioxidantes.
JP6716468B2 (ja)	2014-05-05	2020-07-01	ザボードオブリージェンツオブザユニバーシティーオブテキサスシステム	肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物
KR20170055482A (ko)	2014-09-10	2017-05-19	다이이찌 산쿄 가부시키가이샤	안질환 치료용 및 예방용 서방성 의약 조성물
US11059792B2 (en)	2015-02-12	2021-07-13	Reata Pharmaceuticals, Inc.	Imidazolyl tricyclic enones as antioxidant inflammation modulators
CN105017374B (zh) *	2015-07-20	2017-03-01	山西大学	一种齐墩果酸内酯类衍生物及其制备方法和应用
US20170056373A1 (en) *	2015-09-01	2017-03-02	Syracuse University	Ghrelin o-acyltransferase inhibitors
EA201890767A1 (ru)	2015-09-23	2019-09-30	Рита Фармасьютикалз, Инк.	C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
EA201990560A1 (ru)	2016-09-08	2019-09-30	Регенера Фарма Лтд.	Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии
AU2017356955B2 (en)	2016-11-08	2023-11-09	Reata Pharmaceuticals Holdings, LLC	Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh)	2016-12-16	2024-02-11	美商瑞塔醫藥有限責任公司	用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
CN112654610B (zh)	2018-06-15	2024-12-24	里亚塔医药公司	用于抑制IL-17和RORγ的吡唑和咪唑化合物
EP3810141A1 (en)	2018-06-20	2021-04-28	Reata Pharmaceuticals, Inc.	Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
KR102891865B1 (ko)	2019-07-19	2025-11-26	리아타 파마슈티컬즈, 아이엔씨.	C17 극성-치환된 헤테로방향족 합성 트리터페노이드 및 그의 사용 방법
JP2023524035A (ja) *	2020-04-29	2023-06-08	バイオエイジラブス，インコーポレイテッド	加齢性状態を処置するための低酸素誘導因子プロリルヒドロキシラーゼ阻害剤
IL298008A (en) *	2020-05-09	2023-01-01	Reata Pharmaceuticals Holdings Llc	Methods for treating covid-19 with the help of bardoxolone methyl or its analogs
WO2024145502A1 (en) *	2022-12-29	2024-07-04	The Board Of Regents Of The University Of Texas System	Synthetic triterpenoids and compositions thereof in weight management, skeletal muscle function, and appetite suppression
WO2025251068A1 (en) *	2024-05-31	2025-12-04	Larmor Biosystems, Inc.	Systems and methods for microscale nuclear magnetic resonance-based disease monitoring

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ191586A (en)	1978-10-10	1981-10-19	Sterling Drug Inc	Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US4395423A (en)	1978-10-10	1983-07-26	Sterling Drug Inc.	Polycyclic cyanoketones
US6025395A (en)	1994-04-15	2000-02-15	Duke University	Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6326507B1 (en) *	1998-06-19	2001-12-04	Trustees Of Dartmouth College	Therapeutic compounds and methods of use
US6369101B1 (en)	1999-02-26	2002-04-09	Regents Of The University Of Minnesota	Therapeutic method to treat herpes virus infection
US6365768B1 (en)	1999-05-14	2002-04-02	Nereus Pharmaceuticals, Inc.	Interleukin-1 and tumor necrosis factors-α modulators, syntheses of said modulators and methods of using modulators
US6890946B2 (en)	1999-12-23	2005-05-10	Indiana University Research And Technology Corporation	Use of parthenolide to inhibit cancer
WO2002003996A1 (en)	2000-07-12	2002-01-17	RAJKUMAR, Sujatha	Use of dammarane-type tritepenoid saporins
JP2004509972A (ja)	2000-09-29	2004-04-02	リージェンツ　オブ　ザ　ユニバーシティ　オブ　ミネソタ	酵母に対する殺真菌活性を有するトリテルペン
US6878751B1 (en)	2000-10-19	2005-04-12	Imperial College Of Science Technology And Medicine	Administration of resveratrol to treat inflammatory respiratory disorders
EP1395255A4 (en)	2000-11-28	2007-09-12	Univ Texas	CDDO COMPOUNDS AND COMBINATION THERAPIES THEREOF
US7435755B2 (en)	2000-11-28	2008-10-14	The Trustees Of Dartmouth College	CDDO-compounds and combination therapies thereof
KR20040018341A (ko) *	2001-03-23	2004-03-03	샤이어 바이오켐 인코포레이티드	암치료용 약제 조성물
AU2002308701A1 (en)	2001-05-14	2002-11-25	University Of Maryland, Baltimore	Novel alanine transaminase enzyme and methods of use
US7176237B2 (en)	2002-01-15	2007-02-13	The Trustees Of Dartmouth College	Tricyclic-bis-enone derivatives and methods of use thereof
AU2003303128A1 (en) *	2002-05-13	2004-08-13	Trustees Of Dartmouth College	Inhibitors and methods of use thereof
EP1457206A1 (en)	2003-03-13	2004-09-15	Fournier Laboratories Ireland Limited	Combined use of a fibrate and orlistat for the treatment of obesity
WO2004089357A2 (en)	2003-04-02	2004-10-21	Regents Of The University Of Minnesota	Anti-fungal formulation of triterpene and essential oil
CA2523408A1 (en)	2003-05-09	2004-11-18	Novo Nordisk A\S	Peptides for use in treating obesity
RU2005133970A (ru) *	2003-05-09	2007-06-20	Ново Нордиск А/С (DK)	Пептиды, применяемые для лечения ожирения
US7582674B2 (en)	2003-05-27	2009-09-01	Dsm Ip Assets B.V.	Nutraceutical compositions and use thereof
WO2005042002A2 (en)	2003-10-30	2005-05-12	Entelos, Inc.	Treatment of rhematoid arthritis with flip antagonists
US8288439B2 (en)	2003-11-04	2012-10-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods and compositions for the inhibition of HIV-1 replication
DE602004005617T2 (de)	2003-12-22	2007-12-13	Alcon Inc.	Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
JP2005314381A (ja)	2004-03-30	2005-11-10	Anges Mg Inc	増殖性腎疾患の予防・治療・改善剤
WO2005113761A2 (en)	2004-04-19	2005-12-01	University Of Maryland, Baltimore	Novel alanine transaminase enzymes and methods of use
US7772195B2 (en)	2004-07-29	2010-08-10	Board Of Trustees Of Michigan State University	Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
CA2579231C (en)	2004-09-07	2018-07-10	Pacific Arrow Limited	Anti-tumor compounds with angeloyl groups
WO2007005879A2 (en)	2005-07-01	2007-01-11	The Johns Hopkins University	Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
WO2007127791A2 (en)	2006-04-25	2007-11-08	The Administrators Of The Tulane Educational Fund	New pharmacological method for treatment of neuropathic pain
EP2032594B1 (en)	2006-06-27	2015-09-23	Wellington Laboratories Inc.	Glycyrrhetinic acid derivatives
WO2008016095A1 (en)	2006-08-02	2008-02-07	Santen Pharmaceutical Co., Ltd.	PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
JP2008110962A (ja)	2006-08-02	2008-05-15	Santen Pharmaceut Co Ltd	Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
US8299046B2 (en)	2006-11-17	2012-10-30	Trustees Of Dartmouth College	Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
WO2008064133A1 (en)	2006-11-17	2008-05-29	Trustees Of Dartmouth College	Synthesis and biological activities of new tricyclic-bis-enones (tbes)
WO2008111497A1 (ja)	2007-03-08	2008-09-18	Santen Pharmaceutical Co., Ltd.	トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008136838A1 (en)	2007-05-04	2008-11-13	Trustees Of Dartmouth College	Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en)	2007-08-15	2012-01-03	Reata Pharmaceuticals Inc.	Forms of CDDO methyl ester
US20090048205A1 (en)	2007-08-15	2009-02-19	Colin Meyer	Combination therapy with synthetic triterpenoids and gemcitabine
WO2009058849A1 (en)	2007-10-29	2009-05-07	University Of Rochester	Use of electrophilic compounds for inducing platelet production or maintaining platelet function
HUE043175T2 (hu) *	2008-01-11	2019-08-28	Reata Pharmaceuticals Inc	Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
CN104250280A (zh)	2008-04-18	2014-12-31	里亚塔医药公司	抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
MX339476B (es) *	2008-04-18	2016-05-27	Reata Pharmaceuticals Inc	Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
ES2703274T3 (es)	2008-04-18	2019-03-07	Reata Pharmaceuticals Inc	Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
KR101713140B1 (ko)	2008-04-18	2017-03-08	리타 파마슈티컬스 잉크.	Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
US8071632B2 (en) *	2008-04-18	2011-12-06	Reata Pharmaceuticals, Inc.	Antioxidant inflammation modulators: novel derivatives of oleanolic acid
EP2309860B1 (en)	2008-07-22	2014-01-08	Trustees of Dartmouth College	Monocyclic cyanoenones and methods of use thereof
PL3254675T3 (pl)	2009-02-13	2019-09-30	Reata Pharmaceuticals, Inc.	Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me
SMT202000086T1 (it) *	2010-04-12	2020-03-13	Reata Pharmaceuticals Inc	Bardoxolone metile per il trattamento dell'obesità
US8618125B2 (en)	2011-01-14	2013-12-31	Heptiva LLC	Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance
CN102887936A (zh)	2012-10-24	2013-01-23	苏州晶云药物科技有限公司	2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
CN102875634B (zh)	2012-10-24	2014-08-20	苏州晶云药物科技有限公司	2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型

2011
- 2011-04-12 SM SM20200086T patent/SMT202000086T1/it unknown
- 2011-04-12 US US13/085,338 patent/US10105372B2/en active Active
- 2011-04-12 RS RS20200073A patent/RS59850B1/sr unknown
- 2011-04-12 TW TW100112717A patent/TWI558724B/zh not_active IP Right Cessation
- 2011-04-12 HR HRP20192291TT patent/HRP20192291T1/hr unknown
- 2011-04-12 BR BR112012026112-6A patent/BR112012026112B1/pt active IP Right Grant
- 2011-04-12 CN CN201180028997.6A patent/CN102939089B/zh active Active
- 2011-04-12 SG SG10201808661XA patent/SG10201808661XA/en unknown
- 2011-04-12 KR KR1020127029558A patent/KR101819699B1/ko active Active
- 2011-04-12 MX MX2012011892A patent/MX357596B/es active IP Right Grant
- 2011-04-12 MY MYPI2012004530A patent/MY163031A/en unknown
- 2011-04-12 HU HUE11715645A patent/HUE047994T2/hu unknown
- 2011-04-12 PL PL11715645T patent/PL2558105T3/pl unknown
- 2011-04-12 LT LTEP11715645.5T patent/LT2558105T/lt unknown
- 2011-04-12 EP EP11715645.5A patent/EP2558105B1/en active Active
- 2011-04-12 ME MEP-2020-4A patent/ME03713B/me unknown
- 2011-04-12 SI SI201131840T patent/SI2558105T1/sl unknown
- 2011-04-12 SG SG2012075834A patent/SG184830A1/en unknown
- 2011-04-12 JP JP2013505061A patent/JP5990160B2/ja active Active
- 2011-04-12 ES ES11715645T patent/ES2768204T3/es active Active
- 2011-04-12 AU AU2011240690A patent/AU2011240690C1/en active Active
- 2011-04-12 EA EA201291031A patent/EA026567B1/ru not_active IP Right Cessation
- 2011-04-12 PH PH1/2012/502041A patent/PH12012502041B1/en unknown
- 2011-04-12 CA CA2795320A patent/CA2795320C/en active Active
- 2011-04-12 PT PT117156455T patent/PT2558105T/pt unknown
- 2011-04-12 WO PCT/US2011/032156 patent/WO2011130302A2/en not_active Ceased
- 2011-04-12 DK DK11715645.5T patent/DK2558105T3/da active
- 2011-04-12 NZ NZ602826A patent/NZ602826A/en unknown
2012
- 2012-10-08 ZA ZA2012/07518A patent/ZA201207518B/en unknown
- 2012-10-09 IL IL222273A patent/IL222273B/en active IP Right Grant
- 2012-10-12 CL CL2012002859A patent/CL2012002859A1/es unknown
2018
- 2018-09-13 US US16/130,242 patent/US11911395B2/en active Active
2020
- 2020-01-09 CY CY20201100022T patent/CY1122480T1/el unknown
2024
- 2024-02-26 US US18/587,006 patent/US20240335457A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PH12012502041A1 (en)	2013-01-21
US11911395B2 (en)	2024-02-27
US20110281955A1 (en)	2011-11-17
IL222273A0 (en)	2012-12-31
DK2558105T3 (da)	2020-01-27
TW201139458A (en)	2011-11-16
EP2558105B1 (en)	2019-11-20
EA026567B1 (ru)	2017-04-28
RS59850B1 (sr)	2020-02-28
EA201291031A1 (ru)	2013-04-30
US20190076443A1 (en)	2019-03-14
WO2011130302A3 (en)	2012-01-05
MX357596B (es)	2018-07-16
ZA201207518B (en)	2017-08-30
AU2011240690A1 (en)	2012-10-25
AU2011240690B2 (en)	2014-06-19
BR112012026112B1 (pt)	2020-03-17
HUE047994T2 (hu)	2020-05-28
JP2013523888A (ja)	2013-06-17
PT2558105T (pt)	2020-01-30
CA2795320A1 (en)	2011-10-20
MY163031A (en)	2017-07-31
WO2011130302A2 (en)	2011-10-20
SI2558105T1 (sl)	2020-02-28
JP5990160B2 (ja)	2016-09-07
CN102939089B (zh)	2018-04-10
KR101819699B1 (ko)	2018-01-17
CL2012002859A1 (es)	2013-08-02
PH12012502041B1 (en)	2020-02-26
MX2012011892A (es)	2012-11-30
ME03713B (me)	2021-01-20
NZ602826A (en)	2014-11-28
CA2795320C (en)	2019-01-22
HRP20192291T1 (hr)	2020-03-20
SG184830A1 (en)	2012-11-29
ES2768204T3 (es)	2020-06-22
SG10201808661XA (en)	2018-11-29
SMT202000086T1 (it)	2020-03-13
CY1122480T1 (el)	2021-01-27
US20240335457A1 (en)	2024-10-10
IL222273B (en)	2019-03-31
EP2558105A2 (en)	2013-02-20
CN102939089A (zh)	2013-02-20
AU2011240690C1 (en)	2014-11-06
LT2558105T (lt)	2020-02-10
BR112012026112A2 (pt)	2016-06-28
KR20130096635A (ko)	2013-08-30
TWI558724B (zh)	2016-11-21
US10105372B2 (en)	2018-10-23

Publication	Publication Date	Title
SMT202000086T1 (it)	2020-03-13	Bardoxolone metile per il trattamento dell'obesità
ZA201304280B (en)	2014-08-27	Treatment of jak2-mediated conditions
PL2652193T3 (pl)	2021-01-25	Obróbka
EP2575702A4 (en)	2016-06-22	orthotic device
PT2621569T (pt)	2017-07-14	Dispositivo de tratamento
SG2014014724A (en)	2014-07-30	METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
PH12013500022A1 (en)	2013-02-11	Surface treatment
EP2621498A4 (en)	2014-04-09	COMBINED TREATMENT OF DERMATOLOGICAL CONDITIONS
PL2900230T3 (pl)	2019-02-28	Związki do leczenia otyłości i sposoby ich zastosowania
SMT201900749T1 (it)	2020-03-13	Composizione per il trattamento dell'infertilita'
GB201013573D0 (en)	2010-09-29	Treatment
GB201018622D0 (en)	2010-12-22	Treatment of liquids
EP2595594A4 (en)	2014-03-19	MASSAGER
GB201015970D0 (en)	2010-11-03	Pipe splint
PL2608685T3 (pl)	2014-11-28	Urządzenie do obróbki tytoniu
PL2566419T3 (pl)	2019-07-31	Orteza
TWM402081U (en)	2011-04-21	Bathtub
GB201014369D0 (en)	2010-10-13	Orthotic device
GB201014097D0 (en)	2010-10-06	Treatment
GB2483219B (en)	2018-01-10	Surface Treatment
GB201007519D0 (en)	2010-06-23	Means for inhibiting the expression of rragb
GB201021319D0 (en)	2011-01-26	Treatment
GB201009806D0 (en)	2010-07-21	Sewage treatment
GB201013068D0 (en)	2010-09-15	Liquid treatment
GB201016304D0 (en)	2010-11-10	Treatment device